Epichem Awarded One Year Contract Extension from DND*i*

18 January 2018 – Perth, Australia: PharmAust (ASX:PAA), a clinical-stage oncology company, is pleased to announce that its wholly owned subsidiary, Epichem Pty Ltd, has been awarded a one year extension to its current contract with Drugs for Neglected Diseases *initiative* (DND*i*) (www.dndi.org).

The contract, which was due to finish on 31 December 2017, will now see Epichem continue to provide synthetic & medicinal chemistry support to DND*i*'s drug discovery projects until 31 December 2018. The extension will generate $1.3M in revenues for Epichem during 2018.

Epichem's Managing Director, Dr Wayne Best, said "We are delighted the contract with DND*i* has again been renewed. Epichem has been working with DND*i* for over 10 years and we look forward to continuing our long standing relationship with them on this important work."

Enquiries:

Dr Wayne Best
CEO (Epichem)
Tel: (08) 6167 5200
ceo@epichem.com.au

Dr Richard Hopkins
CEO (PharmAust)
Tel: 0405 656 868
rhopkins@pharmaust.com

About Epichem:
Epichem is a wholly owned subsidiary of the ASX listed company PharmAust Limited. Located in Technology Park, Western Australia, Epichem has been delivering products and services in synthetic and medicinal chemistry to the global drug discovery and pharmaceutical industries in 39 countries worldwide for over 13 years. Epichem has a newly constructed state-of-the-art laboratory and has world class equipment and expertise in synthetic and medicinal chemistry for the cost effective synthesis of drug analogue libraries and intermediates. It also has a rapidly growing catalogue of pharmaceutical reference standards. More information at www.epichem.com.au

About PharmAust (PAA):
PAA is a clinical-stage company developing targeted cancer therapeutics for both humans and animals. The company specialises in repurposing marketed drugs lowering the risks and costs of development. PAA's lead drug candidate is monepantel (MPL), a novel, potent and safe inhibitor of the mTOR pathway - a key driver of cancer. MPL has been evaluated in Phase 1 clinical trials in humans and dogs. MPL treatment was well-tolerated and produced a significant reduction in key prognostic biomarkers. PAA is uniquely positioned to commercialise MPL for treatment of human and veterinary cancers as it advances the drug into Phase 2 clinical trial.